Drug Profile


Alternative Names: Mesupron; WX-671

Latest Information Update: 28 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Wilex
  • Developer RedHill Biopharma; WILEX AG
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Serine endopeptidase inhibitors; Urokinase-type plasminogen activator inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Pancreatic cancer
  • Clinical Phase Unknown Cancer
  • Discontinued Head and neck cancer

Most Recent Events

  • 18 Sep 2017 Clinical trials in Cancer (Combination therapy) in USA (PO)
  • 18 Sep 2017 RedHill Biopharma receives patent allowance for Yeliva® and Mesupron in USA
  • 10 Aug 2017 RedHill plans a phase I/II trial for Pancreatic cancer in Germany in the first half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top